Katie Fanning, Mozart Therapeutics CEO

Mozart Ther­a­peu­tics makes its of­fi­cial de­but, jump­ing in­to the hot Treg R&D field with some big-name in­vestors back­ing it

Treg cells have been get­ting more and more at­ten­tion re­cent­ly among au­toim­mune spe­cial­ists. There’s been Jeff Blue­stone’s Sono­ma, the $157 mil­lion launch of Gen­tiBio …

Endpoints News

Sign up to read this article for free.

Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.